Latest news with #Myriad
The Australian
4 days ago
- Business
- The Australian
Long Shortz: Aroa Biosurgery
Tylah Tully chats with Aroa Biosurgery (ASX:ARX) founder and CEO Brian Ward on the company's FY25 results, posting its first profit since listing on the ASX in 2020. The company had a strong year, reporting total revenue of NZ$84.7 million, 23% growth on FY24. In particular, Myriad™ notched just over NZ$32 million in product revenue, 38% growth on the previous financial year. Watch the video to hear Ward's insights. This video was developed in collaboration with Aroa Biosurgery, a Stockhead client at the time of publishing. The interviews and discussions in this video are opinions only and not financial or investment advice. Viewers should obtain independent advice based on their own circumstances before making any financial decisions.
News.com.au
6 days ago
- Business
- News.com.au
Health Check: Aroa's ‘hero' product propels the wound management house back into black
Aroa shares surge 13% after the company's full-year results exceeded guidance New wound management IPO does the rounds for $35 million Inoviq shares vault up to 58% on early cancer light therapy results Kiwi-based wounds management house Aroa Biosurgery (ASX:ARX) has exceeded its recent revenue and earnings guidance, after a robust second half on the back of its 'hero' Myriad product range. Aroa's revenue came in at NZ$84.7 million for the year to March 2025, 23% higher and slightly above the NZ$81-84 million range the company guided to in late April. Normalised earnings before interest tax depreciation and amortisation (ebitda) were NZ$4.2 million, compared with the previous NZ$3.1 million loss. Once again, the number was a tad above the guided range of NZ$2-4 million. Aroa has also guided to current-year revenue of NZ$92-100 million, 10-20% higher year on year, with ebitda of NZ$5-8 million. CEO Brian Ward stresses the company's 'star product' Myriad has been delivering the goods, with sales up 35%. Myriad is used for complex wounds including trauma and lower limb salvage. Sold via Aroa's partner TELA Bio, sales of its hernia and breast reconstruction tool Ovitex rose 22% Sales of the Endoform wound dressing were flat, as expected. Expanding indications Ward said the company would focus on expanding indications for its products, which are biological materials sourced from ovine intestines. This push is being supported by several clinical studies, such as a lower limb salvage study trial that resulted in quick healing with no complications. 'That's quite different to what we have seen with other technologies,' he says. However, Aroa has 'paused' the rollout of its Symphony product, for hard-to-heal wounds such as diabetic ulcers. This is because the company has won inpatient reimbursement in the US, but not coverage for physicians. The company plans a supportive trial to win full reimbursement. 'The rules are changing and only products with randomised, controlled trials will be reimbursed,' Ward says. 'This will take many rivals out of the market.' Aroa has product approvals across 50 countries, but almost all its revenue derives from the US. CFO James Agnew said the US tariff impact on the company was likely to be around NZ$1.5 million, or around 1% of revenue. Because of transfer pricing arrangements between TELA Bio and Aroa's own US entity, that's far less than the blanket 10% rate Uncle Sam levies on NZ goods. New wound play does the IPO rounds Still on wound management, Tetraherix is defying the barren IPO biotech landscape with a $35 million raising to advance its novel tools for applications including tissue healing, bone regeneration and surgical spacing. Invented by chemical engineer and University of Sydney researcher Dr Ali Fathi, the platform-based tech is the world's first 'biostealth fluid matrix'. Supplied in ready-to-use syringes, the polymer is injected into the relevant anatomy and sets to a 'chewing-gum' consistency that can be easily moulded to suit the application. Eventually, the material breaks down into water and carbon dioxide. Pending expected US Food and Drug Approval, the company hopes to bring its first products to market in the first half of 2026. These are for dental applications and bone regeneration and orthopaedic uses. The company also has tools in the pipeline for scar prevention during surgery and a prostate surgery 'spacer' to protect surrounding tissue (such as the rectum) during radiation therapy. Doing the rounds Joint lead managers Morgans and Barrenjoey are undertaking the institution round which closes next Tuesday, with a limited retail offering open until June 17. The company is expected to list in late June. The shares are offered at $2.88 a pop, amounting to a $155 million market cap and a $115 million enterprise value (allowing for cash on hand). The founder of 'cloud' accounting software giant Xero, Rod Drury is a notable investor. Invion lights up on skin cancer trial The developer of photodynamic therapies (PTDs) for cancers, Invion (ASX:IVX) has passed the initial safety test for its phase I/II non-melanoma skin cancer trial, being carried out in Queensland (of course). A safety review committee found no 'adverse events' among the first treated patients, who were administered Invion's candidate INV-043 as an ointment. What's more, 'early indications show an observable reduction in the lesion size after a single treatment cycle'. Clinician feedback shows patients did not experience any pain during the treatment, 'which compares favourably to currently approved PDT treatments.' By combining oxygen and light, PTDs are known to kill malignant cells and shut down tumors. Known about for more than a century, the science is supported by more than 500 trials. That said, it's been an overlooked area of oncology and Invion is the only listed exemplar. Invion now is proceeding to the second stage of the adaptive trial, which involves dose optimalisation. Meanwhile, the safety data will influence the company's upcoming phase I/II trial for ano-genital cancer, in alliance with the Peter MacCallum Cancer Centre. Known for wild movements, Invion shares soared up to 58% this morning. Inoviq share freeze highlights disclosure dilemmas A quirky aspect of clinical results is they are not validated until they are presented in a prestigious peer-reviewed publication, or a conference of luminaries. Typically, a company will post top-line results earlier and this can lead to investor confusion about what's new and what's merely additional info for the boffins. On Monday, the ASX suspended share trading in cancer drug developer Inoviq (ASX:IIQ) and queried why the company's shares soared 25%, from 37 cents on Wednesday May 21, to last Friday's high of 46.5 cents. Inoviq yesterday pointed to an abstract poster presentation for an upcoming American Society of Clinical Oncology (ASCO) conference published online. This outlined 'the background, methods, results and conclusions underpinning the high-level results' of an independent patient validation study of the company's ovarian cancer test. The results of the blood test were 'outstanding', with more than 94% accuracy. Hold the front page! Okay, let it go: the guts of the results were outlined on December 3 last year – and referred to in subsequent ASX disclosures. Inoviq says: 'some shareholders may have missed or misunderstood the significance of and may believe the abstract contains new or better information, which is materially price sensitive.' The company believes that was not the case and did not 'announce' the abstract to the ASX. Fair enough! After all, there's nothing more frustrating than companies hyping up presentations that contain no genuine news. In old tabloid terms it's known as a Bamix job: a beat up. But like all good tabloid yarns, there's a twist: Inoviq will present further trial information that is price sensitive, to the ASCO powwow in Chicago on Sunday. This prezzo is under embargo until that day and Inoviq plans to announce the 'tightly held' information first thing on Monday. In the meantime, it's best the shares remain untradeable.
National Business Review
6 days ago
- Business
- National Business Review
Aroa shares surge on profit result
Investment 2 mins to read Aroa shares surge on profit result The ASX-listed bioscience company posted a strong second half and its guidance for 2026 is bullish. The company's investment in its core Myriad product is starting to pay off.
Associated Press
21-05-2025
- Business
- Associated Press
Myriad Advisor Solutions Highlights the Power of Succession Planning and 4C Compliance
WAUKEE, Iowa--(BUSINESS WIRE)--May 21, 2025-- Myriad Advisor Solutions (Myriad), a long-established, full-service business advisory firm, is highlighting the power of its proven 4C compliance platform during the 2025 Trade PMR Synergy Conference in Tampa May 27-28. In addition to showcasing 4C's tested capabilities, Myriad continues to lead conversations on business continuity and succession planning through its partnership with the Exit Planning Institute, national speaking engagements, and an American City Business Journals article based on Myriad founder Leigh White's own very personal journey – one that led to the team's realization that continuity and succession planning was vital for the success of any company. Myriad is also excited to be hosting the firm's seventh annual charity golf tournament in Des Moines in June. MYRIAD'S 4C PLATFORM: A SMARTER APPROACH TO COMPLIANCE AND OPERATIONS 4C (Foresee), part of the established MASDefense suite, is Myriad's comprehensive platform, designed to help Registered Investment Advisors (RIAs) gain better control over their compliance and operational environment without adding complexity. Built in direct response to real-world advisor pain points, 4C integrates seamlessly into existing workflows and consolidates essential tools into one secure, streamlined hub. 4C focuses on four core pillars of well-run advisory business: With capabilities like CE credit tracking, audit-ready reports, and integrated cybersecurity protocols, 4C enables RIAs to simplify operations and improve audit readiness, without disrupting what already works. '4C isn't about reinventing the wheel — it's about making the ride smoother,' said Danielle White, CEO of Myriad. 'We've built this platform on everything we've learned from over 15 years of working directly with independent advisors. It's intuitive, integrated, and most importantly — it works.' Myriad will demonstrate the platform's value at the 2025 TradePMR Synergy Conference. SHARPENING THE SAW AT THE CEPA SUMMIT Myriad CTO Leigh White, CEPA®,, and CEO Danielle White, CEPA®, attended the Certified Exit Planner Association (CEPA®) 2025 Summit in May. They returned with fresh perspectives and a renewed commitment to helping business owners shape their futures. While attending the summit, White and White delved into important issues such as the following: 'Exit planning isn't just about leaving the business, it's about building a business that runs with intention, structure, and value every step of the way,' said CEO White. 'It's about creating a legacy. We are devoted to helping our clients build legacies worth leaving.' CTO White added, 'Understanding all the steps necessary to ensure a smooth transition is vital. Bringing in a specialist early can really make the difference because some of these processes must be set into motion years in advance to ensure a seamless exit.' This mission is personal for the Whites. Leigh White's own succession journey, marked by professional accomplishments and personal trials, was recently featured in American City Business Journals' 'In Her Own Words' series. Her story, along with a new Swift Chat interview with host Marie Swift, a powerful reminder that proper planning is essential not only for business continuity but also for personal peace of mind. 'In early 2021, I was diagnosed with breast cancer,' she said. 'You immediately ask yourself 'Do I have my affairs in order?' It's overwhelming, but when you've already planned for the future, it becomes a little easier to focus on what matters most, healing and hope. We are more than just the work we do, and we owe it to ourselves to prepare for life's unexpected turns.' MYRIAD CHARITY GOLF TOURNAMENT 2025 This year marks the seventh annual Myriad Charity Golf Tournament. The 2025 tournament will be held on Thursday, June 19, at Bright Grandview Golf Course in Des Moines, Iowa. It's a fun, relaxed day of golf and community, open to anyone who wants to play and support a good cause. All of the proceeds from the tournament will go directly to the Ronald McDonald House and the Iowa Narcotics Officers Association. Registration includes: Click here for details and registration information. ABOUT MYRIAD ADVISOR SOLUTIONS Established in 2009, this full-service business advisory and solutions firm has been dedicated to its mission of empowering small business owners to achieve their goals by alleviating the operational demands and challenges which growing businesses invariably face. While its focus has primarily been helping breakaway brokers go independent and independent financial advisors reach new levels of success, Myriad Advisor Solutions (Myriad) also works with other types of privately-held businesses on an individual needs-and-interests basis, providing these developing companies with all-encompassing business solutions, operational guidance, and technical support. The company has assisted in launching over 9,500 successful businesses with more than 3,200 locations established nationwide. As a part of that work, Myriad has configured and managed over 5,000 technology networks. It is the umbrella company for two subsidiary firms: Continuum Advantage (which offers with human resources, benefits, payroll, insurance, etc.) and Communications Experts (a telecommunications-focused firm). CEO Danielle White has been with the company since its inception. Leigh White, formerly CEO and President, now leads product development and remains on the leadership team. To learn more, please visit View source version on CONTACT: Media Contact: Grace Vogelzang Impact Communications, Inc. 913-649-5009 [email protected] KEYWORD: UNITED STATES NORTH AMERICA FLORIDA IOWA INDUSTRY KEYWORD: SECURITY DATA MANAGEMENT INSURANCE START-UP TECHNOLOGY HUMAN RESOURCES FINANCE CONSULTING SMALL BUSINESS PROFESSIONAL SERVICES ENTREPRENEUR PHILANTHROPY FUND RAISING TELECOMMUNICATIONS SOFTWARE CONSUMER SOURCE: Myriad Advisor Solutions Copyright Business Wire 2025. PUB: 05/21/2025 07:07 AM/DISC: 05/21/2025 07:06 AM
Yahoo
21-05-2025
- Business
- Yahoo
Myriad Advisor Solutions Highlights the Power of Succession Planning and 4C Compliance
Power of charitable giving driven home with Myriad's seventh annual charity golf tournament WAUKEE, Iowa, May 21, 2025--(BUSINESS WIRE)--Myriad Advisor Solutions (Myriad), a long-established, full-service business advisory firm, is highlighting the power of its proven 4C compliance platform during the 2025 Trade PMR Synergy Conference in Tampa May 27-28. In addition to showcasing 4C's tested capabilities, Myriad continues to lead conversations on business continuity and succession planning through its partnership with the Exit Planning Institute, national speaking engagements, and an American City Business Journals article based on Myriad founder Leigh White's own very personal journey – one that led to the team's realization that continuity and succession planning was vital for the success of any company. Myriad is also excited to be hosting the firm's seventh annual charity golf tournament in Des Moines in June. MYRIAD'S 4C PLATFORM: A SMARTER APPROACH TO COMPLIANCE AND OPERATIONS 4C (Foresee), part of the established MASDefense suite, is Myriad's comprehensive platform, designed to help Registered Investment Advisors (RIAs) gain better control over their compliance and operational environment without adding complexity. Built in direct response to real-world advisor pain points, 4C integrates seamlessly into existing workflows and consolidates essential tools into one secure, streamlined hub. 4C focuses on four core pillars of well-run advisory business: Compliance for evolving regulatory standards Communication that's secure, personalized, and efficient Control over data, permissions and oversight Connection between the platforms and tools RIAs rely on daily With capabilities like CE credit tracking, audit-ready reports, and integrated cybersecurity protocols, 4C enables RIAs to simplify operations and improve audit readiness, without disrupting what already works. "4C isn't about reinventing the wheel — it's about making the ride smoother," said Danielle White, CEO of Myriad. "We've built this platform on everything we've learned from over 15 years of working directly with independent advisors. It's intuitive, integrated, and most importantly — it works." Myriad will demonstrate the platform's value at the 2025 TradePMR Synergy Conference. SHARPENING THE SAW AT THE CEPA SUMMIT Myriad CTO Leigh White, CEPA®,, and CEO Danielle White, CEPA®, attended the Certified Exit Planner Association (CEPA®) 2025 Summit in May. They returned with fresh perspectives and a renewed commitment to helping business owners shape their futures. While attending the summit, White and White delved into important issues such as the following: The Value Acceleration Methodology The importance of business valuation Choosing mastery over mediocrity Why exit planning starts NOW, not when you're "ready" "Exit planning isn't just about leaving the business, it's about building a business that runs with intention, structure, and value every step of the way," said CEO White. "It's about creating a legacy. We are devoted to helping our clients build legacies worth leaving." CTO White added, "Understanding all the steps necessary to ensure a smooth transition is vital. Bringing in a specialist early can really make the difference because some of these processes must be set into motion years in advance to ensure a seamless exit." This mission is personal for the Whites. Leigh White's own succession journey, marked by professional accomplishments and personal trials, was recently featured in American City Business Journals' "In Her Own Words" series. Her story, along with a new Swift Chat interview with host Marie Swift, a powerful reminder that proper planning is essential not only for business continuity but also for personal peace of mind. "In early 2021, I was diagnosed with breast cancer," she said. "You immediately ask yourself 'Do I have my affairs in order?' It's overwhelming, but when you've already planned for the future, it becomes a little easier to focus on what matters most, healing and hope. We are more than just the work we do, and we owe it to ourselves to prepare for life's unexpected turns." MYRIAD CHARITY GOLF TOURNAMENT 2025 This year marks the seventh annual Myriad Charity Golf Tournament. The 2025 tournament will be held on Thursday, June 19, at Bright Grandview Golf Course in Des Moines, Iowa. It's a fun, relaxed day of golf and community, open to anyone who wants to play and support a good cause. All of the proceeds from the tournament will go directly to the Ronald McDonald House and the Iowa Narcotics Officers Association. Registration includes: 18 holes of golf Catered lunch Two drink tickets Awards banquet after the round Click here for details and registration information. ABOUT MYRIAD ADVISOR SOLUTIONS Established in 2009, this full-service business advisory and solutions firm has been dedicated to its mission of empowering small business owners to achieve their goals by alleviating the operational demands and challenges which growing businesses invariably face. While its focus has primarily been helping breakaway brokers go independent and independent financial advisors reach new levels of success, Myriad Advisor Solutions (Myriad) also works with other types of privately-held businesses on an individual needs-and-interests basis, providing these developing companies with all-encompassing business solutions, operational guidance, and technical support. The company has assisted in launching over 9,500 successful businesses with more than 3,200 locations established nationwide. As a part of that work, Myriad has configured and managed over 5,000 technology networks. It is the umbrella company for two subsidiary firms: Continuum Advantage (which offers with human resources, benefits, payroll, insurance, etc.) and Communications Experts (a telecommunications-focused firm). CEO Danielle White has been with the company since its inception. Leigh White, formerly CEO and President, now leads product development and remains on the leadership team. To learn more, please visit View source version on Contacts Media Contact: Grace VogelzangImpact Communications, Inc.913-649-5009GraceVogelzang@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
